Earnings summaries and quarterly performance for Lexeo Therapeutics.
Executive leadership at Lexeo Therapeutics.
R. Nolan Townsend
Detailed
Chief Executive Officer
CEO
EA
Eric Adler
Detailed
Chief Medical Officer and Head of Research
JR
Jenny R. Robertson
Detailed
Chief Legal Officer
JM
Jose Manuel Otero
Detailed
Chief Technical Officer
LT
Louis Tamayo
Detailed
Chief Financial Officer
SS
Sandi See Tai
Detailed
Chief Development Officer
Board of directors at Lexeo Therapeutics.
Research analysts covering Lexeo Therapeutics.
Recent press releases and 8-K filings for LXEO.
Lexeo Therapeutics Provides Updates on Friedreich's Ataxia and Arrhythmogenic Cardiomyopathy Programs
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics is advancing its lead program, LX2006 for Friedreich's ataxia, into a registrational study in 2026. The therapy has demonstrated a meaningful impact on cardiac pathology, with all patients with abnormal heart mass returning to the normal range, and signals of improvement in neurologic disease, achieving a 2-point improvement in the mFARS scale similar to commercially approved therapy. The company expects to provide an update on the final statistical plan and study design in early 2026, following FDA discussions where the agency was open to pooling Phase I/II data with the registrational study and using an earlier time point.
- The company's next most advanced program, treating arrhythmogenic cardiomyopathy (PKP2 mutation), completed Phase I/II enrollment last year and reported early 2026 data showing a 22% reduction in non-sustained ventricular tachycardia compared to a 20% worsening in the natural history study, and a 30% improvement in ejection fraction in one patient. The therapy demonstrated a dose-dependent response in biopsy endpoints and a compelling safety profile.
- Lexeo has completed production of the clinical batch for the pivotal study using its final commercial process, with the FDA having approved the comparability protocol, and also received a CDRP designation to advance innovation in process validation for a BLA.
Feb 12, 2026, 5:30 PM
Lexeo Therapeutics Provides Updates on Friedreich's Ataxia and Arrhythmogenic Cardiomyopathy Programs
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics is advancing its Friedreich's ataxia (FA) gene therapy (LX2006) into a registrational study in 2026. The therapy has shown a meaningful impact on cardiac pathology, with all patients with abnormal heart mass returning to the normal range, and a 2-point improvement in the modified Friedreich's Ataxia Rating Scale (mFARS), similar to commercially approved therapies.
- The company expects to provide an update on the final statistical plan and study design for the FA program in early 2026, following FDA alignment on pooling Phase I/II data and potentially a shorter study duration. The FDA has also approved the comparability protocol for the commercial manufacturing process.
- For its arrhythmogenic cardiomyopathy (PKP2) program, early Phase I/II data showed a 22% reduction in non-sustained ventricular tachycardia (VT), with a 42% delta compared to the natural history study, and a 30% improvement in ejection fraction for the patient with the longest follow-up.
- The PKP2 program demonstrated a positive safety profile with no classic gene therapy-related serious adverse events (SAEs) such as complement activation or liver injury, and no patients in the trial have had their ICDs fire.
Feb 12, 2026, 5:30 PM
Lexeo Therapeutics Provides Updates on Friedreich's Ataxia and Arrhythmogenic Cardiomyopathy Gene Therapy Programs
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics is advancing its lead gene therapy program for Friedreich's ataxia (LX2006), which is moving into a registrational study in 2026. The company expects to provide an update on the final statistical plan and study design in early 2026 following discussions with the FDA.
- LX2006 has demonstrated a meaningful impact on cardiac pathology, with all patients presenting with abnormal heart mass returning to the normal range, and signals of improvement in neurologic disease, including a 2-point improvement in the modified Friedreich's Ataxia Rating Scale (mFARS), similar to commercially approved therapies.
- The company's next most advanced program, targeting arrhythmogenic cardiomyopathy (PKP2), completed Phase I/II enrollment last year and reported early 2026 data showing a 22% reduction in non-sustained ventricular tachycardia (VT), contrasting with a 20% worsening in the natural history study. At 9 months, a 65% reduction in non-sustained VT was observed.
- Lexeo has defined a clear therapeutic window for its PKP2 program, demonstrating a dose-dependent response in biopsy endpoints (vector copy, mRNA, protein) with no classic gene therapy-related serious adverse events (SAEs) such as complement activation or liver injury.
Feb 12, 2026, 5:30 PM
Lexeo Therapeutics Provides Updates on Clinical Programs, Financing, and Strategic Partnerships
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics announced positive data from its Friedreich ataxia cardiomyopathy program (LX2006) in 2025, received breakthrough designation, and expects to initiate the pivotal SUNRISE-FA study in the first half of 2026.
- The company shared recent positive data for its PKP2 arrhythmogenic cardiomyopathy program (LX2020) in early 2026, showing a 22% mean reduction in nonsustained ventricular tachycardia at six months, with over 50% reduction at nine months, and a generally well-tolerated safety profile.
- Lexeo completed two financings totaling $230 million, securing a cash runway into 2028 and funding the Friedreich ataxia registrational study.
- Strategic partnerships include a collaboration with Johnson & Johnson to explore cardiovascular delivery of AAV gene therapies and a partnership to advance novel non-viral cardiac RNA therapeutics with two leading venture funds.
- The company is focusing its pipeline on cardiovascular genetic medicines, with expectations for the FA program launch in the next couple of years, followed by the PKP2 program, and further preclinical programs advancing to late-stage studies.
Jan 14, 2026, 3:30 PM
Lexeo Therapeutics Provides Updates on Clinical Programs, Financing, and Strategic Focus at J.P. Morgan Healthcare Conference
LXEO
New Projects/Investments
Guidance Update
CFO Change
- Lexeo Therapeutics completed $230 million in financings in 2025, securing a cash runway into 2028, and appointed a CFO with commercial finance experience.
- The company's Friedreich's ataxia cardiomyopathy program (LX-2006) announced positive data in 2025, demonstrating a 33% reduction in left ventricular mass index at 12 months, and is expected to initiate its pivotal study, Sunrise-FA2, in H1 2026.
- For its PKP2 arrhythmogenic cardiomyopathy program (LX-2020), Lexeo reported a mean 22% reduction in nonsustained ventricular tachycardia at the high dose (earliest follow-up) and over 50% reduction at 9 months, with a further data update anticipated in Q4 2026.
- Lexeo has strategically focused on its cardiovascular pipeline, forming a partnership with Johnson & Johnson for AAV gene therapies and collaborating with two venture funds on novel non-viral cardiac RNA therapeutics.
Jan 14, 2026, 3:30 PM
Lexeo Therapeutics Provides Updates on Cardiac Genetic Medicines Pipeline and Financial Position
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics is advancing its cardiac genetic medicines pipeline, with its Friedreich's ataxia (FA) cardiomyopathy program (LX-2006) moving towards a registrational study, Sunrise-FA2, expected to initiate in the first half of 2026. Positive data from the Phase 1/2 study showed a 115% increase in frataxin and a 33% reduction in left ventricular mass index at 12 months.
- The company's PKP2 arrhythmogenic cardiomyopathy program (LX-2020) completed enrollment of its Phase 1/2 study, HEROIC-PKP2, and reported a 162% increase in PKP2 expression at the high dose and a 22% reduction in nonsustained ventricular tachycardia at 6 months, with over 50% reduction at 9 months. A regulatory update is expected in 2026, with a data update in Q4 2026.
- Lexeo has secured a strong financial position with $230 million in capital from two financings, providing a cash runway into 2028.
- The company is focused on reshaping heart health through its leading cardiac genetic medicines platform, utilizing a differentiated AAVrh10 capsid and an innovative Sf9 manufacturing platform. It also recently partnered with Johnson & Johnson to explore cardiovascular delivery of AAV gene therapies.
Jan 14, 2026, 3:30 PM
Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics announced positive interim Phase I/II clinical data for LX2020 for the treatment of PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM) on January 12, 2026.
- LX2020 was generally well tolerated across ten participants and demonstrated dose-dependent increases in PKP2 protein expression, with a mean increase of 162% in the high-dose cohorts.
- Clinical data showed improvements in arrhythmia burden in the high-dose cohort, including a 22% mean decrease in non-sustained ventricular tachycardia (NSVT) and a 14% mean decrease in premature ventricular contractions (PVCs).
- Enrollment for the HEROIC-PKP2 trial was completed in Q4 2025, with 12-month data for high-dose participants expected in Q4 2026 and regulatory engagement anticipated in 2026.
Jan 12, 2026, 4:45 PM
Lexeo Therapeutics Presents Interim Phase I-II Data for LX2020 in PKP2-Associated Arrhythmogenic Cardiomyopathy
LXEO
New Projects/Investments
Guidance Update
- Lexeo Therapeutics released interim data from its Phase I-II clinical trial (HEROIC study) for LX2020, a gene therapy for PKP2-associated arrhythmogenic cardiomyopathy (ACM).
- LX2020 demonstrated a favorable safety profile, being well tolerated across all 10 dosed participants with no clinically significant complement activation or new serious adverse events reported.
- The study observed mean increases in PKP2 protein expression, robust vector copy number, and exogenous mRNA, with dose-dependent increases between low and high-dose cohorts.
- Clinically, LX2020 led to stabilization or reduction of premature ventricular contractions (PVCs) and non-sustained ventricular tachycardia (NSVT) in the majority of participants, with the high-dose cohort showing a 14% mean improvement in PVCs and a 22% mean improvement in NSVT.
- Enrollment for the HEROIC study was completed in Q4 2025, and 12-month follow-up data for all high-dose participants are anticipated by Q4 2026.
Jan 12, 2026, 1:00 PM
Lexeo Therapeutics Presents Interim Data for LX2020 in PKP2-associated Arrhythmogenic Cardiomyopathy
LXEO
New Projects/Investments
- Lexeo Therapeutics announced interim data from its LexeoHeroic PKP2 phase 1-2 clinical trial of LX2020 for PKP2-associated arrhythmogenic cardiomyopathy (ACM) on January 12, 2026.
- The treatment with LX2020 was well tolerated across all 10 participants dosed, with no clinically significant complement activation or new serious adverse events reported.
- Preliminary efficacy data showed mean increases in PKP2 protein expression, robust vector copy number, and exogenous mRNA, with dose-dependent increases between low and high-dose cohorts.
- Clinical measures indicated early benefit, with premature ventricular contractions (PVCs) stabilized or reduced in the majority of participants, showing a 14% mean improvement in the high-dose cohort. Non-sustained ventricular tachycardia (NSVT) was also stabilized or reduced in the majority, with a 22% mean improvement in the high-dose cohort.
- Enrollment for the Heroic study was completed in Q4 2025, and Lexeo Therapeutics expects to provide a subsequent data update with 12-month follow-up data for all high-dose participants by Q4 2026.
Jan 12, 2026, 1:00 PM
Lexeo Therapeutics Announces Positive Interim Data for LX2020 in PKP2-associated Cardiomyopathy
LXEO
New Projects/Investments
Product Launch
- Lexeo Therapeutics reported positive interim data from its LexeoHeroic PKP2 phase 1-2 clinical trial for LX2020 in PKP2-associated arrhythmogenic cardiomyopathy (ACM).
- The treatment was well tolerated across all 10 dosed participants, with no clinically significant complement activation or new serious adverse events, although elevations in liver function tests in 5 high-dose participants resolved with modified immunosuppression.
- Preliminary efficacy data showed mean increases in PKP2 protein expression and dose-dependent increases in vector copy number and exogenous mRNA at three months post-dosing.
- Clinically, a 14% mean improvement in premature ventricular contractions (PVCs) and a 22% mean improvement in non-sustained ventricular tachycardia (NSVT) were observed in the high-dose cohort. Additionally, no ICD shocks have been observed in any of the 10 treated patients to date.
- The company completed enrollment in Q4 2025 and expects 12-month follow-up data for all high-dose participants by Q4 2026, with a subsequent data update planned.
Jan 12, 2026, 1:00 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more